wuxiapptec.comHome | WuXi AppTec

Contact Us EN 简 繁Services Platform News Careers Investors WuXi AppTec Global Platform One Vision Our Vision Every Drug Can Be Made and Every Disease Can Be Treated By Building an Open-access Platform with the Most Comprehensive Capabilities and Technologies in the Global Healthcare Industry Our Values Integrity & Dedication, Working Together & Sharing Success; Doing the Right Thing, Doing It Right. Overview Environmental, Social and Governance (ESG) View ESG VideoEnabling Innovation As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated." SEE MORE Services and Solutions An Open Enabling Platform Enabling more than 6,000 innovative customers from more than 30 Countries Small Molecule Drug R&D and Manufacturing Cell Therapy and Gene Therapy Drug R&D and Medical Device Testing Clinical Services Small Molecule Drug R&D and Manufacturing Company Platform Enabling Anyone, Any Company To Become the Most Comprehensive Capability and Technology Platform in the Global Pharmaceutical and Healthcare Industry WuXi Chemistry Provides CRDMO services for new drug development from discovery to commercial SEE MORE WuXi Biology A full spectrum of biology services and solutions supporting stand-alone and integrated projects SEE MORE WuXi Testing Seamless drug and medical device testing services from preclinical testing to clinical trials SEE MORE WuXi Advanced Therapies Global CTDMO offering an integrated end-to-end solution to accelerate time to market for cell and gene therapies SEE MORE News The Latest News about WuXi AppTec WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance’s AMTAGVI™ (lifileucel) for Advanced Melanoma WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site WuXi AppTec Named 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year by Frost & Sullivan WuXi AppTec Continued Solid Growth in the First Three Quarters of 2023 on Top of an Exceptionally Strong Year in 2022, with Profit Growth Continuously Exceeding Revenue Growth WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations (SHANGHAI, April 29, 2024) — WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced its financial results for the first quarter ending March 31, 2024 (Reporting Period”): Read more WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time (SHANGHAI, March 18, 2024) — WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced its financial results for the year ending December 31, 2023 (Reporting Period”) Read more WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance’s AMTAGVI™ (lifileucel) for Advanced Melanoma PHILADELPHIA, PA. February 20, 2024 – WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Drug Administration (FDA) has approved its Philadelphia site to begin the analytical testing and manufacturing of AMTAGVI for Iovance, which received FDA accelerated approval of its Biologics License Application (BLA) on February 16, 2024. Read more WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site Shanghai, China - January 8, 2024WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, announced the commissioning of its two new peptide manufacturing plants, one at its Changzhou facility and another at the new Taixing site in China. This significant expansion has increased the company’s Solid-Phase Peptide Synthesis (SPPS) total reactor volume to 32,000 liters, addressing the surging global demand for peptide therapeutics. Read more WuXi AppTec Named 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year by Frost & Sullivan SHANGHAI, November 8, 2023 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, received the 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan, a growth advisory & growth opportunity analytics firm. Read more WuXi AppTec Continued Solid Growth in the First Three Quarters of 2023 on Top of an Exceptionally Strong Year in 2022, with Profit Growth Continuously Exceeding Revenue Growth (SHANGHAI, October 30, 2023) — WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its financial results for the third quarter and nine months ended September 30, 2023 (Reporting Period”) Read more Careers Welcome to Our Team Become Part of Creating a Better Life Join Us Investors The Latest Financial Reports, Announcements and Resources SEE MORE Contact Us WuXi AppTec Main Offices 288 Fute Zhong Road Waigaoqiao Free Trade Zone Shanghai 200131, China Tel: +86 (21) 5046-1111 Fax: +86 (21) 5046-1000 Enquiries Tel: 400-820-0985 (Mainland China) 857-413-2800 (U.S.) +86 (21) 2066-3734 (Global) Email: wuxiconcierge@wuxiapptec.com Social Media SEE OUR GLOBAL SITES © 2020 WuXi AppTec Terms of Use | Privacy Policy | Transparency in Coverage | 沪ICP备10016157号 | 沪公网安备31011502012242号 © 2020 WuXi AppTec Terms of Use | Privacy Policy | Transparency in Coverage | 沪ICP备10016157号...